Stock Chart

RGEN

$149.37 -4.48%
Score: 57.5 HOLD
1Y Target $145.19 -2.8%
i
1Y Price Target

This target is derived from long-term trendline analysis and projected growth.

Note: Targets are based on the assumption that the current primary trend continues. They should be used as reference points, not guarantees.

Target may adjust dynamically as the stock trend reverses or accelerates.
LEAPs: SELL $170
i
LEAPs Option Signal

Type: SELL growth_1yr
Strike: $170
Premium: $16.60
Expiry: May 15, 2026
Target: $166
Score: -100

LEAPs are long-term options (1+ year) with less time decay.
30D Target: $147.77 - $149.37 UPTREND
i
30D Trendline Target

This is a PROJECTED price range based on extrapolating the current trendline slope forward 30 days.

How it works:
• Draws support and resistance trendlines
• Calculates slope (rate of change)
• Projects lines to 30 days future

Signals:
● STRONG_UPTREND: Steep rise
● UPTREND: Moderate rise
● SIDEWAYS: Flat/Mixed
● DOWNTREND: Falling

⚠️ Not a prediction. Shows trend projection only.

R-squared: 0.64
Vol: 1.42x (vs SPY: 1.1x | vs QQQ: 1.1x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Technical Chart
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About RGEN - Repligen Corp

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics …

Key Statistics

Market Cap $8B
P/E Ratio 14937.00

This RGEN stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track RGEN's price movements with trendlines, gamma walls, and key support/resistance levels.